Skip to main content
Rogaine is the United States brand name for topical minoxidil and holds no marketing authorisation in the European Union. The same molecule is sold in Europe as Regaine, and under generic names such as Lacovin, Alopexy, Regaxidil and Aloxidil.
Rogaine has no EU marketing authorisation for this use. No doctor in the EU — including Hi-Doctor’s — can prescribe it for this use. It may be authorised in another country, or for a different condition. In the United States it is an over-the-counter product, listed on DailyMed with Kenvue Brands LLC as labeller.

​
What can I take instead?

Minoxidil itself — the active ingredient in Rogaine — is available in the EU under authorised brand names. See Minoxidil for the full EU-authorised profile, dosing and evidence.

​
How it works

Applied to the scalp, minoxidil widens small blood vessels and appears to keep hair follicles in their growing phase for longer, although exactly how it acts on hair is still not fully understood.

​
What the studies reported

The core hair-loss trial ran for 48 weeks in men aged 18–49 with vertex-pattern loss, so it does not establish results beyond one year or in other patterns of hair loss. Every trial behind Rogaine is listed on the source page with how many people took part and whether the result is peer-reviewed or a company announcement — a readout is not the same as a peer-reviewed publication.

​
At a glance

Form: 5% topical solution or low-dose tablet. Frequency: daily routine. First changes: months 2–4. Status: prescription only.
Topical solution 5% (50 mg/ml) applied twice daily to a dry scalp; do not rinse for at least 4 hours. Initial shedding around weeks 2–8 is common — this is the old hair making room for new growth, not a worsening.

​
What has been reported

In a 24-week randomised trial of oral minoxidil 5 mg vs topical minoxidil 5% (n=45 per arm), hypertrichosis occurred in 22/45 (49%) on the oral drug vs 11/45 (25%) on topical (P=.02), and headache in 6/45 (14%) vs 1/45 (2%) (P=.046). Scalp eczema was more frequent with topical: 7/45 (16%) vs 1/45 (2%).
In a retrospective multicentre study of 1,404 patients treated for at least 3 months, the most frequent adverse effect was hypertrichosis (15.1%, causing withdrawal in 0.5%). Systemic effects: lightheadedness 1.7%, fluid retention 1.3%, tachycardia 0.9%, headache 0.4%, periorbital oedema 0.3%, insomnia 0.2% — leading to discontinuation in 1.2% of patients.

​
Who it is not suitable for

  • Pregnancy or breastfeeding
  • Children under 18
  • Known hypersensitivity to minoxidil or propylene glycol (for the solution)
  • Active scalp disease — broken skin, severe eczema or psoriasis on the scalp until treated
  • Significant cardiovascular disease or phaeochromocytoma — discuss with the doctor before any oral use

​
How Hi-Doctor handles it

1

Weeks 1–8

Build the daily routine.
2

Months 2–4

Early density changes.
3

Months 4–6

Response assessed by the doctor.
4

Ongoing

Keep the routine to keep the results.
Because Rogaine itself has no EU authorisation, a Hi-Doctor doctor reviewing a hair-loss case works from the authorised alternatives — see Minoxidil. Medication, if prescribed, is paid separately at a pharmacy; see pricing.

​
Common questions

Rogaine is the United States brand name for topical minoxidil. It holds no marketing authorisation in the European Union, so no doctor in the EU — including Hi-Doctor’s — can prescribe it. The same molecule is sold in Europe as Regaine and under generic names.
Minoxidil itself — the active ingredient in Rogaine — is available in the EU under authorised brand names. A doctor can prescribe topical minoxidil solution or foam, or in selected cases a low-dose oral tablet, after reviewing your case.
Itching, dermatitis, rash and unwanted hair growth away from the scalp are common with the topical form. Headache and breathlessness are common; dizziness and nausea are uncommon. Palpitations and chest pain are rare.
The core hair-loss trial ran for 48 weeks in men aged 18–49 with vertex-pattern loss. It does not establish results beyond one year or in other patterns of hair loss.
In a 24-week randomised trial of oral minoxidil 5 mg vs topical minoxidil 5%, hypertrichosis occurred in 49% on the oral drug vs 25% on topical, and headache in 14% vs 2%. Scalp eczema was more frequent with topical.

​
Start a consultation

Hair-growth consultation

Answer the hair-growth questionnaire and a registered doctor reviews it. They decide whether treatment is appropriate, which one, and at what dose — and declining is a normal outcome. See what it costs and how the review works.
This page is reference information, not medical advice and not a prescription. Whether a medicine is appropriate for you is decided by a registered doctor after reviewing your consultation.